Fig. 5

ADT-adjusted Cox regression of biochemical failure-free survival (left) and overall rates of biochemical failure-free survival at 12, 24, 36 and 48 months (right) for ¹⁸F-flotufolastat-guided salvage radiotherapy, vs conventional salvage radiotherapy in a subgroup of patients receiving SRT to the prostate bed only.